Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.
Eli Lilly's weight-loss drug misses Wall Street expectations, shares tumble
Eli Lilly fell short of Wall Street sales estimates for its weight-loss and diabetes drugs on Wednesday, hit by a decrease in U.S. wholesale inventory and sending its shares down more than 10% premarket.
Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high manufacturing costs and fluctuating inventory levels as it races to keep up with soaring demand for its blockbuster anti-obesity treatments.
This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body weight in four weeks.
Eli Lilly Gets Nod to Launch Weight-Loss Drug in Hong Kong - Bloomberg News
The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales rose 31% to $17.
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided awareness of Zepbound ... is actually not very high," CEO David Ricks said on an earnings call Wednesday morning.
FDA approves a new weight loss drug, Zepbound from Eli Lilly
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
FDA adds new warning to weight loss drugs including Wegovy
The U.S. Food and Drug Administration has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a higher risk of inhaling gastric contents into their lungs while under anesthesia.
FDA adds new warning to popular weight loss drugs
The Food and Drug Administration has updated labels for popular weight loss drugs like Ozempic and Wegovy.
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...
Yahoo Finance7d
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...